1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIHR NICE rolling funding opportunity (EME Programme) is sponsored by NIHR (National Institute for Health and Care Research). The NIHR NICE Efficacy and Mechanism Evaluation (EME) Programme funds high-quality studies that address research recommendations from NICE guidance published or updated in the last five years. Projects must focus on health-related outcomes and fill clear evidence gaps.
Get alerted about grants like this
Get emailed when new opportunities from “NIHR (National Institute for Health and Care Research)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Hit enter to search or ESC to close Funding Calls Database « All Calls National Institute for Health and Care research UK , NIHR NICE rolling call (EME Programme): The Efficacy and Mechanism Evaluation Programme is accepting Stage 1 applications to this funding opportunity. The programme is interested in receiving applications to meet recommendations in research identified in NICE guidance that has been published or updated since 2015.
Proposals must be within the remit of the EME Programme and the primary outcome measure must be health related. This call is also open in the Health Technology Assessment (HTA), Health and Social Care Delivery Research (HSDR) and Public Health Research (PHR) programmes for proposals which fall within the remit of those programmes – applicants should apply directly to the relevant programme.
All proposals submitted must fall within the scope of the EME Programme. The Efficacy and Mechanism Evaluation (EME) Programme funds ambitious studies evaluating interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research in the mechanisms of diseases and treatments.
EME is a partnership between the Medical Research Council (MRC) and the NIHR. The EME Programme looks to attract studies with novel methodological designs that deliver results more efficiently, reduce the study timeline, and maximise the knowledge gained.
The translational research it supports covers a wide range of new and repurposed interventions, such as diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS. Deadline First stage (LOI / pre-proposal) Deadline Full Application Grant Decision – Final Decision – Awarding Interested in joining this call?
Clinical trial - any phase Other data generation study (e.g. retrospective analysis, case series etc) Pilot study Non-dilutive (grant, donation etc) National Institute for Health and Care research UK The REMEDi4ALL project has received funding from the European Union’s Horizon Europe Research & Innovation programme under grant agreement No 101057442.
About Us REMEDi4ALL is an EU-funded research initiative transforming drug repurposing by building a state-of-the-art platform, uniting global expertise, and accelerating access to cost-effective treatments for patients in need. DEMO PROJECTS To test the platform’s viability and robustness we support real-world projects on infectious diseases, rare cancers, and rare/ultra rare diseases.
i DR The International Drug Repurposing (iDR) Conference Series is an annual global conference series where key opinion leaders from research and patient communities, funders, regulators and representatives from the private sector participate to collectively advance innovative drug repurposing in Europe and beyond.
Explore the iDR conference series 2026 International Drug Repurposing Conference Medicines Reimagined Newsletter DRUG REPURPOSING CONCIERGE Get expert guidance for your drug repurposing project. Through a 30-minute consultation, our experts help you explore scientific support, regulatory pathways, advocacy opportunities and funding options.
With 250+ inquiries answered and a 100% response rate, the Concierge is your first stop within REMEDi4ALL for navigating the path from discovery to market. PROJECT PARTNERING PORTAL Advance your repurposing project with REMEDi4ALL through a formalised partnership.
Following a thorough evaluation process, selected projects are onboarded to work hand-in-hand with multidisciplinary teams, providing support from early discovery to regulatory approval to patient access. All potential applicants are strongly advised to engage with the Drug Repurposing Concierge before submitting partnering proposals.
REMED i 4ALL Repurposing Academy A range of training resources designed to provide a comprehensive understanding of the drug repurposing landscape. REMEDi4ALL Digital Academy The Digital Academy is our online home for on demand training on repurposing. REMEDi4ALL Bootcamps Our Bootcamps are short, in person training events that provide the chance to meet others in the drug repurposing field.
REMEDi4ALL Webinars Our webinars provide accessible, live training on specific stages of the repurposing journey. REMEDi4ALL Hackathon Join a small team of international trainees to learn on a week-long residential course where you aim to plan the development of a repurposing candidate. Resources We’re a dynamic community dedicated to drug repurposing, we produce a wide range of valuable resources.
Explore our collection here. In-silico Drug Repurposing Catalogue Practical Guide to Creating Joint Funding Calls for Drug Repurposing Research Framework for Judging the Project Value of Repurposed Medicines MEDICINES REIMAGINED Join a vibrant community to connect and collaborate to advance drug repurposing. FUNDERS NETWORK Public and private funders worldwide driving innovation in drug repurposing.
According to the current listing, eligibility includes: Research teams addressing a NICE research recommendation within the remit of the EME Programme. Confirm the full requirements in the official notice before applying.
The published deadline was August 5, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
NIHR NICE rolling funding opportunity (EME Programme) is funded by NIHR (National Institute for Health and Care Research). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward interdisciplinary projects that leverage AI, machine learning, and advanced data science to address pressing questions in biomedical and public health research. It seeks to advance fundamental scientific and engineering contributions across disciplines to solve key health problems.
PMHCA (HRSA-26-058) makes $9.79 million available for up to 22 awards of up to $445,000 to build tele-consultation networks that help pediatric primary care providers manage children's behavioral health. The catch buried in the eligibility section: applicants must NOT already hold a PMHCA award — which effectively reserves the new-state lane for the eight unfunded states and territories, plus tribes everywhere. Here's how to read it and what wins.
Read articleRWJF's Health Equity Research for Action puts up ~20 grants of up to $500,000 — but demands a two-year community partnership and a community co-PI. Here's the strategy, set against the brightest foundation-giving outlook since 2022.
Read articleCMS awarded all 50 states a slice of the $50 billion Rural Health Transformation Program on December 29, 2025 — first-year checks average $200M, ranging from $147M to $281M. The federal application is closed and you cannot apply to CMS. The money reaches hospitals, clinics, and nonprofits only as state subawards, and those competitions open through 2026. Here is how the formula worked, what the funds can and cannot buy, and how to position for a subaward before the money starts flowing.
Read article